Pfizer says tilrekimig showed skin clearance in Phase 2 study
Pfizer said tilrekimig showed significant skin clearance in a Phase 2 atopic dermatitis study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Study
Pfizer presented detailed results from an ongoing Phase 2 study investigating tilrekimig in adults with moderate-to-severe atopic dermatitis. The study met its primary endpoint, demonstrating a statistically significant increase in skin clearance.